Dr Preety Jain, Dr Garima Uikey, Dr Manish Verma, Dr Pranjil Mandloi, Dr Vikas Pal, Dr Vipin Kumar Dubey, Dr Jyoti Dane


Head and neck cancers are among the 10 most common
cancers globally and are the most common cancers in
developing countries, especially in South East Asia. In India,it
accounts for one fourth of male cancers and one tenth of
female cancers.Oral cancers are most common amongst all
head and neck squamous cell carcinoma(HNSCC). This
mainly attributed to tobacco,areca nut, alcohol, etc.[1]
According to Cancer statistics of India cancer of oral cavity
and lung account for over 25 % of cancer death in male [2].
Concurrent chemoradiation,has become the standard
treatment option for locally advanced head and neck
squamous cell cancer, since several randomized trials
r e p o r t e d a s i g n i  c a n t s u r v i v a l b e n e  t o f a d d i n g
chemotherapy to radiation over radiation alone [3-
6].Cisplatin is among the most common agents used in
combination with radiotherapy as well as one of the most
studied. It has radiosensitizing properties and it's toxicity does
not overlap radiotherapy [4].In an attempt to increase to local
control in advanced head and neck cancers chemotherapy
has been used before or after surgery and has been
associated with good clinical response. Combined
chemotherapy and radiation used simultaneously to get
synergistic benet against head and neck cancers has been
associated with high level of response in in-operable disease.
T h e m o s t c o m m o n d r u g s u s e d a r e c i s p l a t i n , 5 -
uorouracil,hydroxyurea and mitomycin [7]. Carboplatin has
radiosensitizing properties and has lesser renal and
gastrointestinal toxicities than cisplatin and is considered an
effective option in National Comprehensive Cancer Network
(NCCN) guidelines for patients unt for cisplatin. Phase II
studies of carboplatin based CTRT showed complete
response of 65%-70% ,similar to those seen in cisplatin[8].

Full Text:



Imran Ali, Waseem A. Wani and kishwar Saleem Cancer scenario in India with future perspective.

ICMR;Cancer Statistics 2018.

Brizel DM,Albers ME,Fisher SR,rt al.Hyperfractionation irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338;1798-804.

Aldestien DJ,Liy,Adams G2,et al.An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer,Jclin. Oncol 2003;21:92-8.

Forastier AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-8.

Denis F,Garaud P,Bardet E,et al. Final results of the 94-01 French head and neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced stage oropharynx carcinoma. JClinOncol 2004;22:69-76.

Savita Lasrado et al; Role of concomitant chemoradiation in locally advanced head and neck cancers.

Al-Saraf M, Hussain N.Head and Neck cancers:Present status and future prospect of adjuvant chemotherapy Cancer Invest 1995;13:41-53.

Marcu L,Van Doorn T,Olver I, Cisplatin and radiotherapy in the treatment of locally advanced head and neck cancer-review of their cooperation Acta Oncol 2003;42(4);315-325.

Jeremic B,Shibainoto Y,Stanisavljevic R, Milojevic L, Milic B,Nikolic N. Radiation therapy alone or with concurrent low dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma head and neck :A prospective randomized trial :Radiotherapy Oncol 1997;43:29-37

Chitapanarux L, Lorvidhaya V,Kmnerdsupaphon P,Sumitsuwan,et al. Chemoradiation comparing versus carboplatin in Locally advanced nasopharyngeal Cancer:Randomized non Inferiority , open trial. Eur J Cancer 2007;43;1399-406.

Dutta S,Ghorais,Choudhury KB, Majumdar A. Radical treatment of locally advanced head and neck cancer with concurrent chemoradiation-cisplatin versus carboplatin: A randomized comparative phase III trial. Clin cancer Investig J 2013;2:122-7.


  • There are currently no refbacks.